Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)

This is a randomized-controlled interventional treatment study with three arms of comparable demographics to evaluate the efficacy of PPC Pharmaceuticals EZC Pak (& EZC Pak+D) to improve the severity and duration of the common cold or a URI in individuals. It is hypothesized that study participants will experience a positive impact on the duration and severity of their cold/URI while using EZC Pak (&EZC Pak+D). The second study objective is to examine if patients are accepting the test product as an alternative to antibiotics.

Inclusion criteria

• Male or female over 18 years old
• Must be in good health (don't report any medical conditions asked in the screening questionnaire)
• Seeking OTC remedies to reduce the severity and duration of their common cold symptoms, when they arise
• Must have a thermometer at home
• Must have a blood pressure monitor at home
• Ideally, uses one of the following devices: Apple Watch, Oura Ring, FitBit, other fitness trackers

Exclusion criteria

• Unwilling to try the test product for their cold
• Has any of the following medical conditions:

• ragweed or daisy allergy
• chronic seasonal allergies
• liver disease
• autoimmune or connective tissue disorder (e.g., rheumatoid arthritis, lupus, multiples sclerosis, HIV)
• alcohol consumption more than 7 drinks per week, or more than 3 drinks per occasion
• IV drug use
• renal disease
• females that are pregnant, want to become pregnant for the duration of the study, or who are breastfeeding